Clinical Trial Update: Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of derazantinib (ARQ 087) in adults with advanced solid tumors carrying FGFR genetic alterations has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibroblast Growth Factor Receptor Altered Solid Tumors
• Solid Tumors

Drugs mentioned

• Derazantinib (derazantinib)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-28